Supriya Lifescience Limited (SUPRIYA.NS)
INR 638.35
(-1.05%)
INR 638.35
(-1.05%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 54.88 Million INR | -75.57% |
| 2022 | 224.68 Million INR | -18.04% |
| 2021 | 274.15 Million INR | -62.03% |
| 2020 | 721.94 Million INR | -14.58% |
| 2019 | 845.2 Million INR | -8.5% |
| 2018 | 923.69 Million INR | -29.15% |
| 2017 | 1.3 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.91 Million INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 54.88 Million INR | -75.57% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 54.88 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 57.71 Million INR | 0.0% |
| 2022 Q4 | 224.68 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 364.17 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 224.68 Million INR | -18.04% |
| 2021 Q2 | 729.09 Million INR | 0.0% |
| 2021 FY | 274.15 Million INR | -62.03% |
| 2021 Q4 | 274.15 Million INR | 0.0% |
| 2020 Q3 | 605.66 Million INR | 0.0% |
| 2020 FY | 721.94 Million INR | -14.58% |
| 2020 Q4 | 721.94 Million INR | 19.2% |
| 2019 FY | 845.2 Million INR | -8.5% |
| 2018 FY | 923.69 Million INR | -29.15% |
| 2017 FY | 1.3 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Biocon Limited | 162.76 Billion INR | 99.966% |
| Blue Jet Healthcare Limited | 16.12 Million INR | -240.236% |
| Concord Biotech Limited | 97.37 Million INR | 43.641% |
| Dishman Carbogen Amcis Limited | 23.12 Billion INR | 99.763% |
| Jubilant Ingrevia Limited | 7.4 Billion INR | 99.259% |
| Lyka Labs Limited | 586.5 Million INR | 90.643% |
| Panacea Biotec Limited | 209.9 Million INR | 73.854% |
| Piramal Pharma Limited | 47.1 Billion INR | 99.883% |
| SMS Lifesciences India Limited | 1 Billion INR | 94.551% |
| Syngene International Limited | 5.55 Billion INR | 99.012% |
| TAKE Solutions Limited | 370.85 Million INR | 85.202% |
| Zota Health Care Limited | 952.84 Million INR | 94.24% |